A Biotech Startup Won a Patent to Combine Elements of Weed and Psychedelics
It’s based on the theory that the benefits of psychedelic plants and fungi come from a combination of chemicals working together
Whether aiming to enhance spiritual growth or brighten the music at Lollapalooza, people have been combining cannabis and psilocybin “magic” mushrooms recreationally for ages. But a small biotech startup called CaaMTech Inc. just became the first to patent the idea.
The patent covers a whole range of cannabinoids — chemical compounds produced by marijuana plants, such as THC or CBD — mixed with a bevy of chemicals related to psilocybin mushrooms. It details myriad formulations, including dried powder, pills, gummies, and edibles, with a blanket of proposed applications for psychological disorders. The company, based in the Seattle suburb of Issaquah, hopes investors will want to license these formulations, which each combine a cannabinoid with a psilocybin derivative, either to treat mental health or entertain a yet-to-exist recreational market. The U.S. Patent and Trademark Office awarded the patent in mid-January.
“The single drug will often behave differently than combinations of the drugs,” CaaMTech CEO and co-founder Andrew Chadeayne, PhD, told Future…